Stephen B. Howell, M.D. - Publications

Affiliations: 
Moores Cancer Center University of California, San Diego, La Jolla, CA 
Area:
medical oncology, pharmacology
Website:
http://moores.ucsd.edu/howelllab/people.html

83 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Kim B, Sun S, Varner JA, Howell SB, Ruoslahti E, Sailor MJ. Securing the Payload, Finding the Cell, and Avoiding the Endosome: Peptide-Targeted, Fusogenic Porous Silicon Nanoparticles for Delivery of siRNA. Advanced Materials (Deerfield Beach, Fla.). e1902952. PMID 31267590 DOI: 10.1002/adma.201902952  1
2019 Bertucci A, Kim KH, Kang J, Zuidema JM, Lee SH, Kwon EJ, Kim D, Howell SB, Ricci F, Ruoslahti E, Jang HJ, Sailor MJ. Tumor-Targeting, MicroRNA-Silencing Porous Silicon Nanoparticles for Ovarian Cancer Therapy. Acs Applied Materials & Interfaces. PMID 31251556 DOI: 10.1021/acsami.9b07980  1
2018 Local A, Zhang H, Benbatoul KD, Folger P, Sheng X, Tsai CY, Howell SB, Rice WG. APTO-253 Stabilizes G-quadruplex DNA, Inhibits MYC Expression, and Induces DNA Damage in Acute Myeloid Leukemia Cells. Molecular Cancer Therapeutics. 17: 1177-1186. PMID 29626127 DOI: 10.1158/1535-7163.MCT-17-1209  1
2018 Tsai CY, Sun S, Zhang H, Local A, Su Y, Gross LA, Rice WG, Howell SB. APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency. Molecular Cancer Therapeutics. 17: 1167-1176. PMID 29626126 DOI: 10.1158/1535-7163.MCT-17-0834  1
2016 Bompiani KM, Tsai CY, Achatz FP, Liebig JK, Howell SB. Copper transporters and chaperones CTR1, CTR2, ATOX1, and CCS as determinants of cisplatin sensitivity. Metallomics : Integrated Biometal Science. 8: 951-62. PMID 27157188 DOI: 10.1039/c6mt00076b  1
2015 Tsai CY, Liebig JK, Tsigelny IF, Howell SB. The copper transporter 1 (CTR1) is required to maintain the stability of copper transporter 2 (CTR2). Metallomics : Integrated Biometal Science. 7: 1477-87. PMID 26205368 DOI: 10.1039/c5mt00131e  1
2015 Yamamoto T, Tsigelny IF, Götz AW, Howell SB. Cisplatin inhibits MEK1/2. Oncotarget. 6: 23510-22. PMID 26155939 DOI: 10.18632/oncotarget.4355  1
2014 Lin X, Shang X, Howell SB. Integrin αV control of Cu homeostasis and cisplatin sensitivity. Cell Cycle (Georgetown, Tex.). 13: 3317-8. PMID 25485574 DOI: 10.4161/15384101.2014.973746  1
2014 Shang X, Lin X, Howell SB. Claudin-4 controls the receptor tyrosine kinase EphA2 pro-oncogenic switch through β-catenin. Cell Communication and Signaling : Ccs. 12: 59. PMID 25344320 DOI: 10.1186/s12964-014-0059-5  1
2014 Wang Y, Ma J, Shen H, Wang C, Sun Y, Howell SB, Lin X. Reactive oxygen species promote ovarian cancer progression via the HIF-1α/LOX/E-cadherin pathway. Oncology Reports. 32: 2150-8. PMID 25174950 DOI: 10.3892/or.2014.3448  1
2014 Tsai CY, Larson CA, Safaei R, Howell SB. Molecular modulation of the copper and cisplatin transport function of CTR1 and its interaction with IRS-4. Biochemical Pharmacology. 90: 379-87. PMID 24967972 DOI: 10.1016/j.bcp.2014.06.019  1
2014 Abada PB, Howell SB. Cisplatin induces resistance by triggering differentiation of testicular embryonal carcinoma cells. Plos One. 9: e87444. PMID 24475288 DOI: 10.1371/journal.pone.0087444  1
2014 Quail JF, Tsai CY, Howell SB. Characterization of a monoclonal antibody capable of reliably quantifying expression of human Copper Transporter 1 (hCTR1). Journal of Trace Elements in Medicine and Biology : Organ of the Society For Minerals and Trace Elements (Gms). 28: 151-9. PMID 24447817 DOI: 10.1016/j.jtemb.2013.12.003  1
2013 Gu L, Hall DJ, Qin Z, Anglin E, Joo J, Mooney DJ, Howell SB, Sailor MJ. In vivo time-gated fluorescence imaging with biodegradable luminescent porous silicon nanoparticles. Nature Communications. 4: 2326. PMID 23933660 DOI: 10.1038/ncomms3326  1
2013 Lin X, Shang X, Manorek G, Howell SB. Regulation of the Epithelial-Mesenchymal Transition by Claudin-3 and Claudin-4. Plos One. 8: e67496. PMID 23805314 DOI: 10.1371/journal.pone.0067496  1
2013 Safaei R, Adams PL, Mathews RA, Manorek G, Howell SB. The role of metal binding and phosphorylation domains in the regulation of cisplatin-induced trafficking of ATP7B. Metallomics : Integrated Biometal Science. 5: 964-72. PMID 23803742 DOI: 10.1039/c3mt00131h  1
2013 Shang X, Lin X, Manorek G, Howell SB. Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1. Molecular Pharmacology. 83: 85-94. PMID 23053666 DOI: 10.1124/mol.112.079798  1
2012 Shang X, Lin X, Alvarez E, Manorek G, Howell SB. Tight junction proteins claudin-3 and claudin-4 control tumor growth and metastases. Neoplasia (New York, N.Y.). 14: 974-85. PMID 23097631  1
2012 Tsai CY, Finley JC, Ali SS, Patel HH, Howell SB. Copper influx transporter 1 is required for FGF, PDGF and EGF-induced MAPK signaling. Biochemical Pharmacology. 84: 1007-13. PMID 22842628 DOI: 10.1016/j.bcp.2012.07.014  1
2012 Abada PB, Larson CA, Manorek G, Adams P, Howell SB. Sec61β controls sensitivity to platinum-containing chemotherapeutic agents through modulation of the copper-transporting ATPase ATP7A. Molecular Pharmacology. 82: 510-20. PMID 22710939 DOI: 10.1124/mol.112.079822  1
2012 Tsigelny IF, Sharikov Y, Greenberg JP, Miller MA, Kouznetsova VL, Larson CA, Howell SB. An all-atom model of the structure of human copper transporter 1. Cell Biochemistry and Biophysics. 63: 223-34. PMID 22569840 DOI: 10.1007/s12013-012-9358-x  1
2012 Safaei R, Adams PL, Maktabi MH, Mathews RA, Howell SB. The CXXC motifs in the metal binding domains are required for ATP7B to mediate resistance to cisplatin. Journal of Inorganic Biochemistry. 110: 8-17. PMID 22459168 DOI: 10.1016/j.jinorgbio.2012.02.016  1
2011 Park JS, Kinsella JM, Jandial DD, Howell SB, Sailor MJ. Cisplatin-loaded porous Si microparticles capped by electroless deposition of platinum. Small (Weinheim An Der Bergstrasse, Germany). 7: 2061-9. PMID 21630444 DOI: 10.1002/smll.201100438  1
2011 Xiao L, Gu L, Howell SB, Sailor MJ. Porous silicon nanoparticle photosensitizers for singlet oxygen and their phototoxicity against cancer cells. Acs Nano. 5: 3651-9. PMID 21452822 DOI: 10.1021/nn1035262  1
2011 Kanatani I, Lin X, Yuan X, Manorek G, Shang X, Cheung LH, Rosenblum MG, Howell SB. Targeting granzyme B to tumor cells using a yoked human chorionic gonadotropin. Cancer Chemotherapy and Pharmacology. 68: 979-90. PMID 21327682 DOI: 10.1007/s00280-011-1573-4  1
2011 Yuan X, Lin X, Manorek G, Howell SB. Challenges associated with the targeted delivery of gelonin to claudin-expressing cancer cells with the use of activatable cell penetrating peptides to enhance potency. Bmc Cancer. 11: 61. PMID 21303546 DOI: 10.1186/1471-2407-11-61  1
2011 Blair BG, Larson CA, Adams PL, Abada PB, Pesce CE, Safaei R, Howell SB. Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo. Molecular Pharmacology. 79: 157-66. PMID 20930109 DOI: 10.1124/mol.110.068411  1
2010 Larson CA, Adams PL, Blair BG, Safaei R, Howell SB. The role of the methionines and histidines in the transmembrane domain of mammalian copper transporter 1 in the cellular accumulation of cisplatin. Molecular Pharmacology. 78: 333-9. PMID 20519567 DOI: 10.1124/mol.110.064766  1
2010 Larson CA, Adams PL, Jandial DD, Blair BG, Safaei R, Howell SB. The role of the N-terminus of mammalian copper transporter 1 in the cellular accumulation of cisplatin. Biochemical Pharmacology. 80: 448-54. PMID 20451502 DOI: 10.1016/j.bcp.2010.04.030  1
2010 Blair BG, Larson CA, Adams PL, Abada PB, Safaei R, Howell SB. Regulation of copper transporter 2 expression by copper and cisplatin in human ovarian carcinoma cells. Molecular Pharmacology. 77: 912-21. PMID 20194531 DOI: 10.1124/mol.109.062836  1
2010 Howell SB, Safaei R, Larson CA, Sailor MJ. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Molecular Pharmacology. 77: 887-94. PMID 20159940 DOI: 10.1124/mol.109.063172  1
2010 Larson CA, Adams PL, Jandial DD, Blair BG, Safaei R, Howell SB. Corrigendum to " The role of the N-terminus of mammalian copper transporter 1 in the cellular accumulation of cisplatin" [Biochem. Pharmacol. 80 (2010) 448-454] Biochemical Pharmacology. 80: 1768. DOI: 10.1016/j.bcp.2010.08.006  1
2009 Jandial DD, Messer K, Farshchi-Heydari S, Pu M, Howell SB. Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer model. Gynecologic Oncology. 115: 362-6. PMID 19775736 DOI: 10.1016/j.ygyno.2009.08.028  1
2009 Yuan X, Lin X, Manorek G, Kanatani I, Cheung LH, Rosenblum MG, Howell SB. Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors. Molecular Cancer Therapeutics. 8: 1906-15. PMID 19567823 DOI: 10.1158/1535-7163.MCT-09-0106  1
2009 Blair BG, Larson CA, Safaei R, Howell SB. Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4312-21. PMID 19509135 DOI: 10.1158/1078-0432.CCR-09-0311  1
2009 Jandial DD, Farshchi-Heydari S, Larson CA, Elliott GI, Wrasidlo WJ, Howell SB. Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 553-60. PMID 19147760 DOI: 10.1158/1078-0432.CCR-08-2081  1
2009 Safaei R, Maktabi MH, Blair BG, Larson CA, Howell SB. Effects of the loss of Atox1 on the cellular pharmacology of cisplatin. Journal of Inorganic Biochemistry. 103: 333-41. PMID 19124158 DOI: 10.1016/j.jinorgbio.2008.11.012  1
2009 Larson CA, Blair BG, Safaei R, Howell SB. The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs. Molecular Pharmacology. 75: 324-30. PMID 18996970 DOI: 10.1124/mol.108.052381  1
2008 Safaei R, Otani S, Larson BJ, Rasmussen ML, Howell SB. Transport of cisplatin by the copper efflux transporter ATP7B. Molecular Pharmacology. 73: 461-8. PMID 17978167 DOI: 10.1124/mol.107.040980  1
2007 Kong SD, Luong A, Manorek G, Howell SB, Yang J. Acidic hydrolysis of N-Ethoxybenzylimidazoles (NEBIs): potential applications as pH-sensitive linkers for drug delivery. Bioconjugate Chemistry. 18: 293-6. PMID 17261055 DOI: 10.1021/bc060224s  1
2007 Samimi G, Kishimoto S, Manorek G, Breaux JK, Howell SB. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin. Cancer Chemotherapy and Pharmacology. 59: 301-12. PMID 16770583 DOI: 10.1007/s00280-006-0271-0  0.48
2006 Holzer AK, Howell SB. The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Research. 66: 10944-52. PMID 17108132 DOI: 10.1158/0008-5472.CAN-06-1710  1
2006 Holzer AK, Manorek GH, Howell SB. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Molecular Pharmacology. 70: 1390-4. PMID 16847145 DOI: 10.1124/mol.106.022624  1
2006 Lin X, Howell SB. DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance. Molecular Cancer Therapeutics. 5: 1239-47. PMID 16731756 DOI: 10.1158/1535-7163.MCT-05-0491  1
2006 Holzer AK, Varki NM, Le QT, Gibson MA, Naredi P, Howell SB. Expression of the human copper influx transporter 1 in normal and malignant human tissues. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 54: 1041-9. PMID 16709730 DOI: 10.1369/jhc.6A6970.2006  1
2006 Lin X, Okuda T, Trang J, Howell SB. Human REV1 modulates the cytotoxicity and mutagenicity of cisplatin in human ovarian carcinoma cells. Molecular Pharmacology. 69: 1748-54. PMID 16495473 DOI: 10.1124/mol.105.020446  1
2006 Lin X, Trang J, Okuda T, Howell SB. DNA polymerase zeta accounts for the reduced cytotoxicity and enhanced mutagenicity of cisplatin in human colon carcinoma cells that have lost DNA mismatch repair. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 563-8. PMID 16428501 DOI: 10.1158/1078-0432.CCR-05-1380  1
2006 Cheng TC, Manorek G, Samimi G, Lin X, Berry CC, Howell SB. Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells. Cancer Chemotherapy and Pharmacology. 58: 384-95. PMID 16404635 DOI: 10.1007/s00280-005-0171-8  0.28
2006 Samimi G, Howell SB. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters. Cancer Chemotherapy and Pharmacology. 57: 781-8. PMID 16170571 DOI: 10.1007/s00280-005-0121-5  0.84
2005 Safaei R, Larson BJ, Cheng TC, Gibson MA, Otani S, Naerdemann W, Howell SB. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Molecular Cancer Therapeutics. 4: 1595-604. PMID 16227410 DOI: 10.1158/1535-7163.MCT-05-0102  1
2005 Okuda T, Lin X, Trang J, Howell SB. Suppression of hREV1 expression reduces the rate at which human ovarian carcinoma cells acquire resistance to cisplatin. Molecular Pharmacology. 67: 1852-60. PMID 15758147 DOI: 10.1124/mol.104.010579  1
2005 Safaei R, Katano K, Larson BJ, Samimi G, Holzer AK, Naerdemann W, Tomioka M, Goodman M, Howell SB. Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 756-67. PMID 15701866  0.44
2005 Safaei R, Howell SB. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Critical Reviews in Oncology/Hematology. 53: 13-23. PMID 15607932 DOI: 10.1016/j.critrevonc.2004.09.007  1
2005 Samimi G, Manorek G, Castel R, Breaux JK, Cheng TC, Berry CC, Los G, Howell SB. cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistance. Cancer Chemotherapy and Pharmacology. 55: 1-11. PMID 15378272 DOI: 10.1007/s00280-004-0819-9  0.24
2004 Wu F, Lin X, Okuda T, Howell SB. DNA polymerase zeta regulates cisplatin cytotoxicity, mutagenicity, and the rate of development of cisplatin resistance. Cancer Research. 64: 8029-35. PMID 15520212 DOI: 10.1158/0008-5472.CAN-03-3942  1
2004 Holzer AK, Katano K, Klomp LW, Howell SB. Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 6744-9. PMID 15475465 DOI: 10.1158/1078-0432.CCR-04-0748  1
2004 Safaei R, Holzer AK, Katano K, Samimi G, Howell SB. The role of copper transporters in the development of resistance to Pt drugs. Journal of Inorganic Biochemistry. 98: 1607-13. PMID 15458823 DOI: 10.1016/j.jinorgbio.2004.05.006  0.32
2004 Samimi G, Safaei R, Katano K, Holzer AK, Rochdi M, Tomioka M, Goodman M, Howell SB. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 4661-9. PMID 15269138 DOI: 10.1158/1078-0432.CCR-04-0137  0.28
2004 Katano K, Safaei R, Samimi G, Holzer A, Tomioka M, Goodman M, Howell SB. Confocal microscopic analysis of the interaction between cisplatin and the copper transporter ATP7B in human ovarian carcinoma cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 4578-88. PMID 15240550 DOI: 10.1158/1078-0432.CCR-03-0689  0.16
2004 Holzer AK, Samimi G, Katano K, Naerdemann W, Lin X, Safaei R, Howell SB. The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Molecular Pharmacology. 66: 817-23. PMID 15229296 DOI: 10.1124/mol.104.001198  0.36
2004 Samimi G, Katano K, Holzer AK, Safaei R, Howell SB. Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. Molecular Pharmacology. 66: 25-32. PMID 15213293 DOI: 10.1124/mol.66.1.25  0.52
2004 Lin X, Zhang Q, Rice JR, Stewart DR, Nowotnik DP, Howell SB. Improved targeting of platinum chemotherapeutics: The antitumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models European Journal of Cancer. 40: 291-297. PMID 14728945 DOI: 10.1016/j.ejca.2003.09.022  1
2004 Safaei R, Katano K, Samimi G, Naerdemann W, Stevenson JL, Rochdi M, Howell SB. Cross-resistance to cisplatin in cells with acquired resistance to copper. Cancer Chemotherapy and Pharmacology. 53: 239-46. PMID 14648017 DOI: 10.1007/s00280-003-0736-3  0.36
2003 Samimi G, Varki NM, Wilczynski S, Safaei R, Alberts DS, Howell SB. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 5853-9. PMID 14676106  0.12
2003 Katano K, Safaei R, Samimi G, Holzer A, Rochdi M, Howell SB. The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells. Molecular Pharmacology. 64: 466-73. PMID 12869652 DOI: 10.1124/mol.64.2.466  0.32
2002 Katano K, Kondo A, Safaei R, Holzer A, Samimi G, Mishima M, Kuo YM, Rochdi M, Howell SB. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Research. 62: 6559-65. PMID 12438251  0.24
2002 de las Alas MM, Los G, Lin X, Kurdi-Haidar B, Manorek G, Howell SB. Identification of transdominant-negative genetic suppressor elements derived from hMSH2 that mediate resistance to 6-thioguanine. Molecular Pharmacology. 62: 1198-206. PMID 12391284  1
2002 Lin X, Okuda T, Holzer A, Howell SB. The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Molecular Pharmacology. 62: 1154-9. PMID 12391279  0.08
2002 Mishima M, Samimi G, Kondo A, Lin X, Howell SB. The cellular pharmacology of oxaliplatin resistance. European Journal of Cancer (Oxford, England : 1990). 38: 1405-12. PMID 12091073 DOI: 10.1016/S0959-8049(02)00096-5  0.36
2001 Niedner H, Christen R, Lin X, Kondo A, Howell SB. Identification of genes that mediate sensitivity to cisplatin. Molecular Pharmacology. 60: 1153-60. PMID 11723219  1
2001 Kondo A, Safaei R, Mishima M, Niedner H, Lin X, Howell SB. Hypoxia-induced enrichment and mutagenesis of cells that have lost DNA mismatch repair. Cancer Research. 61: 7603-7. PMID 11606400  1
2001 Lin X, Gately DP, Hom D, Mishima M, Los G, Howell SB. Quantification of tumor cell injury in vitro and in vivo using expression of green fluorescent protein under the control of the GADD153 promoter. International Journal of Cancer. 91: 555-62. PMID 11251981 DOI: 10.1002/1097-0215(200002)9999:9999<::AID-IJC1083>3.0.CO;2-Q  1
2001 Lin X, Ramamurthi K, Mishima M, Kondo A, Christen RD, Howell SB. P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Research. 61: 1508-16. PMID 11245458  1
2000 Lin X, Ramamurthi K, Mishima M, Kondo A, Howell SB. p53 interacts with the DNA mismatch repair system to modulate the cytotoxicity and mutagenicity of hydrogen peroxide. Molecular Pharmacology. 58: 1222-9. PMID 11093757 DOI: 10.1124/MOL.58.6.1222  1
2000 Samimi G, Fink D, Varki NM, Husain A, Hoskins WJ, Alberts DS, Howell SB. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 6: 1415-21. PMID 10778972  0.24
1999 Lin X, Kim HK, Howell SB. The role of DNA mismatch repair in cisplatin mutagenicity. Journal of Inorganic Biochemistry. 77: 89-93. PMID 10626359  1
1999 Lin X, Howell SB. Effect of loss of DNA mismatch repair on development of topotecan-, gemcitabine-, and paclitaxel-resistant variants after exposure to cisplatin. Molecular Pharmacology. 56: 390-5. PMID 10419559  1
1998 Kurdi-Haidar B, Heath D, Naredi P, Varki N, Howell SB. Immunohistochemical analysis of the distribution of the human ATPase (hASNA-I) in normal tissues and its overexpression in breast adenomas and carcinomas Journal of Histochemistry and Cytochemistry. 46: 1243-1248. PMID 9774623 DOI: 10.1177/002215549804601104  1
1998 Kurdi-Haidar B, Hom DK, Flittner DE, Heath D, Fink L, Naredi P, Howell SB. Dual cytoplasmic and nuclear distribution of the novel arsenite- stimulated human ATPase (hASNA-I) Journal of Cellular Biochemistry. 71: 1-10. PMID 9736449 DOI: 10.1002/(SICI)1097-4644(19981001)71:1<1::AID-JCB1>3.0.CO;2-#  1
1996 Kurdi-Haidar B, Aebi S, Heath D, Enns RE, Naredi P, Hom DK, Howell SB. Isolation of the ATP-binding human homolog of the arsA component of the bacterial arsenite transporter Genomics. 36: 486-491. PMID 8884272 DOI: 10.1006/geno.1996.0494  1
1995 Naredi P, Heath DD, Enns RE, Howell SB. Cross-resistance between cisplatin, antimony potassium tartrate, and arsenite in human tumor cells Journal of Clinical Investigation. 95: 1193-1198. PMID 7883968 DOI: 10.1172/JCI117768  1
1993 Lindnér P, Heath DD, Shalinsky DR, Howell SB, Naredi P, Hafström L. Regional lymphatic drug exposure following intraperitoneal administration of 5-fluorouracil, carboplatin, and etoposide Surgical Oncology. 2: 105-112. PMID 8252198 DOI: 10.1016/0960-7404(93)90019-U  1
1990 Andrews PA, Jones JA, Varki NM, Howell SB. Rapid emergence of acquired cis-diamminedichloroplatinum (II) resistance in an in vivo model of human ovarian carcinoma Cancer Communications. 2: 93-100. PMID 2372473 DOI: 10.3727/095535490820874641  1
Show low-probability matches.